Drug
Fiboflapon clinical trials
Also written GSK2190915.
Includes 1 study of Fiboflapon sodium.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
FP 100 (1)
Studies
Open first, then newest update. How each study uses fiboflapon is read from its arms, and is right about nine times in ten.
Testing it · 13
- Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once DailyCompletedPhase 2GlaxoSmithKlineNCT01147744Written as GSK2190915 100mg
- A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following ExerciseCompletedPhase 2GlaxoSmithKlineNCT00812929Written as GSK2190915
- A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915ACompletedPhase 1GlaxoSmithKlineNCT01318980Written as GSK2190915 100mg milled tablet
- A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of RosuvastatinCompletedPhase 1GlaxoSmithKlineNCT01411111Written as GSK2190915 30mg
- GSK2190915A - Bioavailability StudyCompletedPhase 1GlaxoSmithKlineNCT02224521Written as GSK2190915 Solution.
- GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese SubjectsCompletedPhase 1GlaxoSmithKlineNCT00955383Written as GSK2190915
- GSK2190915 Pediatric StudyWithdrawnPhase 2GlaxoSmithKlineNCT01286844Written as GSK2190915A 5mg
- Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of AgeCompletedPhase 2GlaxoSmithKlineNCT01156792Written as GSK2190915 100
- Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for AsthmaCompletedPhase 2GlaxoSmithKlineNCT01248975Written as GSK2190915 200mg QD (AM)
- GSK2190915 Neutrophilic Asthma StudyCompletedPhase 2GlaxoSmithKlineNCT01471665Written as GSK2190915 100mg
- Study to Evaluate GSK2190915 in Subjects With Mild AsthmaCompletedPhase 2GlaxoSmithKlineNCT00812773Written as GSK2190915
- Study in Mild Asthmatic PatientsCompletedPhase 2GlaxoSmithKlineNCT00748306Written as GSK2190915 - 100mcg
- A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.WithdrawnPhase 1GlaxoSmithKlineNCT01721135Written as GSK2190915 100mg
Codes
What other systems call fiboflapon · ClinicalTrials.gg INT005711
- UNII (FDA) Y1NA96IX3TFIBOFLAPONConfirmed FDA, Wikidata
- Wikidata Q27294145fiboflaponConfirmed FDA, Wikidata
- NCI Thesaurus C169978FiboflaponOne source FDA
- DrugBank DB06346One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Y1NA96IX3T | FIBOFLAPON | Confirmed FDA, Wikidata |
| Wikidata | Q27294145 | fiboflapon | Confirmed FDA, Wikidata |
| NCI Thesaurus | C169978 | Fiboflapon | One source FDA |
| DrugBank | DB06346 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.